CClinicalTrials.gg
Sign In
CompletedNCT00222482Updated Aug 9, 2007

Depakote ER in Borderline Personality Disorder

An interventional study of Depakote ER in Borderline Personality Disorder, sponsored by University of Minnesota. Completed. Open to participants aged 21 Years to 55 Years. Per ClinicalTrials.gov, last updated 2007-08-09.

Sponsored by University of Minnesota · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Study summary

This study examines the effect of Depakote ER versus placebo in a randomized trial of borderline personality disorder. Patients all participate in DBT therapy and those who are not responsive are assigned to either Depakote ER or placebo for up to 12 weeks. Borderline Personality Symtoms are measured and side-effects are assessed.

02

Conditions studied

  • Borderline Personality Disorder

Keywords

  • Borderline Personality Disorder
03

In context

Personality Disorders

336 studies on the registry are indexed under Personality Disorders; 48 are open to participants now.

This study's enrollment of 15 is below the median of 75 across 229 interventional studies indexed under Personality Disorders.

Browse Personality Disorders studies →

Lead sponsor

University of Minnesota is the lead sponsor of 1,184 studies on the registry; 195 are open to participants now.

Of its 132 completed or terminated interventional studies of FDA-regulated products, 91 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:Male or female patients with the diagnosis of borderline personality disorder between the ages of 21 adn 55 years old. Must be in good physical health -

Exclusion Criteria:Major psychiatric illness on Axis I - schizophrenia or bipolar disorder. May not have current MDD. May not be dependent on illicit substances or alcohol.

-

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
15 participants

Interventions

  • DrugDepakote ER
06

What researchers measure

Primary outcomes

  1. Symptom Checklist 90

Secondary outcomes

  1. Barratt Impulsivity Scale

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry. 1999 Nov 15;46(10):1429-35. doi: 10.1016/s0006-3223(99)00128-6. PubMed 10578457 ↗
  • Stoffers-Winterling JM, Storebo OJ, Pereira Ribeiro J, Kongerslev MT, Vollm BA, Mattivi JT, Faltinsen E, Todorovac A, Jorgensen MS, Callesen HE, Sales CP, Schaug JP, Simonsen E, Lieb K. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD012956. doi: 10.1002/14651858.CD012956.pub2. PubMed 36375174 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 9, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00222482
Lead sponsor
University of Minnesota
Collaborators
Abbott, Schulz, S. Charles, M.D.
First posted
Sep 22, 2005
Start date
Mar 2003
Completion
Sep 2005
Last update
Aug 9, 2007

Study contacts

Sellamnn C Schulz, M.D.
principal investigator · Department of Psychiatry, University of Minnesota Medical School

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Personality Disorders→

Other studies from this sponsor

University of Minnesota

Start the discussion